(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Results and outcomes of use of multicatheter interstitial high-dose-rate (HDR) brachytherapy (BT) to deliver accelerated partial-breast irradiation (APBI) in a large cohort of women treated in a three-physician private practice setting over 10 years and 9 months are reported.

Richard B. Young, BA, Clinton A. Medbery III, MD, Marianne M. Young, MD, Astrid E. Morrison, MD; Frank C. Love Cancer Institute, St. Anthony Hospital

Purpose: To report results and outcomes of use of multicatheter interstitial high-dose-rate (HDR) brachytherapy (BT) to deliver accelerated partial-breast irradiation (APBI) in a large cohort of women treated in a three-physician private practice setting over 10 years and 9 months.

Materials and Methods: A total of 241 selected patients with Tis-2 N0-1mic breast cancer without an extensive intraductal component and with negative surgical margins were treated after breast-conserving surgery (BCS) with APBI using HDR BT. Three physicians performed the procedures as part of a comprehensive radiation oncology practice. Median patient age was 61 years. Dosage regimen was initially 34 Gy in 10 fractions over 4 elapsed days; subsequently, 32 Gy in 8 fractions over 3–4 elapsed days was used. Target volume was the surgical resection bed with a 1.5–2.0-cm margin. Ultrasound guidance was used in 231 cases, and mammographic stereotactic guidance was used in 10 cases. Overall median follow-up was 67.8 months and 67.4 months in surviving patients. Local breast and regional control, cancer-specific survival (CSS), disease-free survival (DFS), overall survival (OS), late effects, and cosmesis were evaluated.

Results: Four (1.54%) local recurrences were observed. Four (1.54%) “elsewhere” breast failures (different quadrant) were observed. All local and elsewhere failures recurred 18 to 42 months after treatment. Twenty patients died of intercurrent disease, five died of breast cancer, and one is alive with metastatic breast cancer. OS and CSS rates were 89.6% and 97.9%, respectively, with a median follow-up of 67.4 months. Cosmesis was excellent or good in 96.7% of cases. Fat necrosis requiring surgical intervention occurred in 28 patients (10.8%). Median V200 in patients who developed necrosis was 13.6 cc; median V200 in those without development of necrosis was 12.0 cc. Five (2.1%) patients developed telangiectasia > 1 cm2. Three (1.25%) patients developed breast abscess requiring surgical intervention.

Conclusions: APBI using HDR multicatheter interstitial implants is feasible in small private practice with dedicated brachytherapists, yielding excellent long-term results comparable with large academic institutional series and clinical trials and also comparing favorably with the more common external beam regimens.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content